AL-37350A, also known as 4,5-dihydropyrano-ñ-methyltryptamine (4,5-DHP-AMT), is a serotonin receptor agonist and tricyclic tryptamine derivative related to the psychedelic tryptamine 5-MeO-AMT. It acts as a potent and selective agonist for the serotonin receptor 5-HT<sub>2A</sub>, with a K<sub>i</sub> of 2.0nM, and moderate selectivity over the related 5-HT<sub>2B</sub> and 5-HT<sub>2C</sub> receptors. The drug has been shown to have ocular hypotensive activity in animal models, suggesting it may be useful for the treatment of glaucoma. AL-37350A was first described in the scientific literature by Jesse May and colleagues in 2003.